On April 11, 2019 Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting epigenetic causes of cancers, reported that Daniela Y. Santiesteban, Ph.D., Business Development Manager, will present at the World Orphan Drug Congress USA 2019 being held April 10-12, 2019 in Oxon Hill, Maryland (Press release, Salarius Pharmaceuticals, APR 11, 2019, View Source [SID1234535121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of Salarius’ presentation are as follows:

Event:

World Orphan Drug Congress USA 2019

Presentation:

Seclidemstat: A reversible LSD-1 inhibitor for treatment of Ewing’s sarcoma

Date:

April 12, 2019

Time:

12:35 p.m. (Eastern Time)

Location:

Gaylord National Harbor Hill, Oxon Hill, Maryland

About Seclidemstat

Seclidemstat (also known as SP-2577) is an investigational agent currently being evaluated in clinical trials. It is a small molecule in development by Salarius Pharmaceuticals which inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme regulating gene expression. LSD1 has been implicated in various types of cancer, with higher levels of LSD1 associated with poor patient prognosis. Seclidemstat has been shown to inhibit LSD1’s demethylation and scaffolding properties and has demonstrated potent therapeutic activity in preclinical models of Ewing sarcoma, a rare pediatric/adolescent bone cancer. In 2H2018 Salarius started a Phase 1 trial of Seclidemstat in relapsed/refractory Ewing sarcoma and plans to complete the dose escalation portion around the end of 2019.